Icon

SYNRIBO (nda203585)- (3.5MG/VIAL)

OMACETAXINE MEPESUCCINATE TEVA PHARMS INTL
3.5MG/VIAL
No No
2026-Oct-26 2017-Oct-26
2019-Oct-26 None
None No
SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
0 0 0
Total Other Developers None
Drugs with Suitability No
3.5MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.